A grey photography background with a formal headshot photo of Muhammed Murtaza, MBBS, PhD, wearing a dark blue suit and tie.

Muhammed Murtaza, MBBS, PhD

Associate Professor

  • Division of Surgical Oncology
  • Director of the Center for Human Genomics and Precision Medicine

murtaza@surgery.wisc.edu

Education

  • Bachelor of Medicine and Bachelor of Surgery, Aga Khan University Medical College
  • PhD, Medical Science, Cancer Research UK Cambridge Institute, University of Cambridge

Research Interests

Dr. Murtaza was awarded a three-year, $1 million Cooperative Award (UH3) from the National Cancer Institute. Read more here.

Dr. Murtaza and Dr. Zafar were awarded a $50,000 Translational Basic and Clinical Research Pilot Award from the UW Institute for Clinical and Translational Research and the UW Carbone Cancer Center. Read more here.

Recent Publications

  • Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells.
    Shankar K, Zingler-Hoslet I, Tabima DM, Zima S, Shi L, Gimse K, Forsberg MH, Katta V, Davis SZ, Maldonado D, Russell BE, Murtaza M, Tsai SQ, Ayuso JM, Capitini CM, Saha K
    Mol Ther 2025 Jan 14;
    [PubMed ID: 39815622]

  • Colon Cancer Survival Among South Asian Americans: A Cross-Sectional Analysis of a National Dataset.
    Ahmed KS, Marcinak CT, LoConte NK, Krebsbach JK, Virani SS, Schiefelbein AM, Varley P, Walker M, Ghias K, Murtaza M, Zafar SN
    J Surg Res 2024 Jul; 299: 269-281
    [PubMed ID: 38788463]

  • ASO Visual Abstract: Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
    Marcinak CT, Praska CE, Vidri RJ, Taylor AK, Krebsbach JK, Ahmed KS, LoConte NK, Varley PR, Afshar M, Weber SM, Abbott DE, Mathew J, Murtaza M, Burkard ME, Churpek MM, Zafar SN
    Ann Surg Oncol 2024 Jan; 31(1): 552-553
    [PubMed ID: 37805945]

  • Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
    Marcinak CT, Praska CE, Vidri RJ, Taylor AK, Krebsbach JK, Ahmed KS, LoConte NK, Varley PR, Afshar M, Weber SM, Abbott DE, Mathew J, Murtaza M, Burkard ME, Churpek MM, Zafar SN
    Ann Surg Oncol 2024 Jan; 31(1): 488-498
    [PubMed ID: 37782415]

  • Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
    Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin ZB, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald BR, McDaniel T, Trent JM, Baehner FL, Murtaza M, Pal SK
    JCO Precis Oncol 2023 Apr; 7: e2200543
    [PubMed ID: 37027813]

All Publications on PubMed